Hybridoma technology represents the traditional methodology employed for generating monoclonal antibodies. At Creative Biolabs, leveraging our robust and established hybridoma platform, we offer tailored, comprehensive services encompassing antigen design, animal immunization, clone screening, and antibody characterization. This ensures the production of monoclonal antibodies that precisely align with the final application needs of our esteemed clients.

Overview of Hybridoma Technology

Hybridoma technology involves the fusion of myeloma cells, which possess the ability to divide indefinitely in culture, with B-lymphocytes-immune cells responsible for antibody production. This process yields hybrid cells, or hybridomas, which inherit the antibody - generating prowess of B-cells and the perpetual growth characteristics of myeloma cells. These hybridomas undergo rigorous screening to pinpoint those that exclusively secrete antigen-specific antibodies. Following identification, the antibodies are then produced and purified for research applications.

Fig.1 Schematic representation of the hybridoma technology.

Detailed Procedures

1. Antigen Preparation

• Formulate the antigen (protein, peptide, etc.) to stimulate an immune response.
• Ensure purity and high quality.

2. Animal Immunization

• Inject the antigen into an animal (typically a mouse).
• Administer multiple doses over time to boost the immune response.
• Harvest spleen to isolate B lymphocytes.

3. Cell Fusion

• Fuse B lymphocytes with myeloma cells using chemical (PEG) or physical (electric pulse) methods.
• The resulting hybridomas combine antibody-producing capability with immortalized growth.

4. Hybridoma and Subclone Screening

• Culture hybridomas in a selective medium (e.g., HAT) to eliminate non-fused cells.
• Screen and subclone hybridomas to ensure monoclonal antibody production.

5. Antibody Characterization and Preparation

• Culture-selected hybridomas to produce large quantities of antibodies.
• Purify antibodies using affinity chromatography.
• Characterize antibodies for specificity, affinity, and other properties.

The Advantages of the Hybridoma Platform

• High Specificity and Affinity

Monoclonal antibodies generated through our hybridoma platform exhibit exceptional specificity for their targets and often possess high affinity.

• Consistency and Reproducibility

Each hybridoma clone produces a uniform antibody population, ensuring consistent results across experiments and batches, critical for reliable research data.

• Cost-Effectiveness

Compared to other antibody production methods, hybridoma-derived antibodies often offer a more cost-effective solution, especially for long-term studies or large-scale production runs.

• Established and Trusted

With decades of proven success, hybridoma technology remains a cornerstone in antibody development, offering a robust and well-understood framework for researchers worldwide.

Why Us?

Creative Biolabs boasts extensive expertise in developing hybridoma monoclonal antibodies, offering a streamlined and efficient process that encompasses several key advantages:

• Customized Target Analysis

We conduct a thorough analysis of target characteristics to tailor animal immunization protocols, ensuring optimal antibody specificity and affinity.

• Efficient Hybridoma Fusion & Screening

Utilizing electrofusion for hybridoma creation, we enhance fusion efficiency and cell viability. Implementing a range of screening techniques, including FCM (Flow Cytometry), IHC (Immunohistochemistry), WB (Western Blotting), and neutralizing activity assays, in the subcloning stage, significantly boosts screening accuracy and efficiency.

• Minimized Contaminants

By adopting serum-free cell culture, we minimize the risk of animal-derived contaminants in antibody production, enhancing product purity and safety.

• Scalable Production

Our capabilities span from producing micrograms to kilograms of monoclonal antibodies, catering to a wide range of research and therapeutic needs.

Featured Services

• Hyperdoma™ Platform
• Omni-Hybridoma™ Technology
• Magic Hybridoma™ Technology

FAQs

1. Q: What are the characteristics of antibodies produced by hybridoma technology?

   A: Monoclonal antibodies generated through hybridoma technology exhibit a high degree of specificity and maintain a consistent binding affinity for their intended target antigen.

2. Q: How are monoclonal antibodies purified from hybridoma cultures?

   A: Monoclonal antibodies can be purified from hybridoma cultures using various techniques, such as affinity chromatography, ion exchange chromatography, or gel filtration.

3. Q: Are there any requirements for immunogen purity?

   A: For mouse monoclonal antibodies, a protein antigen purity above 90% is essential to prevent nonspecific binding to impurities.

Reach out to us today to discover how our hybridoma platform can expedite the progress of your project.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.